New Indication Approved for Vimpat As Monotherapy for Treating Seizures

Drugmaker UCB Sept. 1 said that the Food and Drug Administration approved a supplemental new drug application (sNDA) for Vimpat (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.

The company said in a statement that this is a new indication for Vimpat, “which is already approved in the U.S. as adjunctive treatment for partial-onset seizures in patients in this age group.” The new indication means that adults with partial-onset seizures can be initiated on Vimpat monotherapy, and patients already on an anti-epileptic drug can be converted to Vimpat monotherapy. ...